ADMA Biologics’ (ADMA) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of ADMA Biologics (NASDAQ:ADMA) in a research report released on Tuesday,Benzinga reports. Cantor Fitzgerald currently has a $25.00 target price on the biotechnology company’s stock.

Other research analysts have also recently issued reports about the company. Raymond James upped their price objective on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th. HC Wainwright lifted their target price on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, November 8th.

ADMA Biologics Stock Performance

NASDAQ:ADMA opened at $16.91 on Tuesday. The company’s 50-day moving average is $16.67 and its two-hundred day moving average is $17.96. ADMA Biologics has a 1-year low of $5.88 and a 1-year high of $23.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The firm has a market capitalization of $4.00 billion, a price-to-earnings ratio of 60.39 and a beta of 0.75.

Hedge Funds Weigh In On ADMA Biologics

Several large investors have recently made changes to their positions in the stock. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in ADMA Biologics by 1.3% in the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 50,466 shares of the biotechnology company’s stock valued at $865,000 after purchasing an additional 645 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its position in shares of ADMA Biologics by 1.3% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 55,600 shares of the biotechnology company’s stock worth $954,000 after buying an additional 700 shares during the period. Summit Investment Advisors Inc. grew its stake in shares of ADMA Biologics by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 23,560 shares of the biotechnology company’s stock valued at $404,000 after buying an additional 746 shares in the last quarter. Mutual of America Capital Management LLC raised its holdings in shares of ADMA Biologics by 2.1% in the 4th quarter. Mutual of America Capital Management LLC now owns 35,807 shares of the biotechnology company’s stock valued at $614,000 after buying an additional 751 shares during the period. Finally, Maryland State Retirement & Pension System lifted its stake in ADMA Biologics by 1.1% during the 4th quarter. Maryland State Retirement & Pension System now owns 79,607 shares of the biotechnology company’s stock worth $1,365,000 after acquiring an additional 897 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.